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Abstract
Gluten-containing cereals are a main food staple present in the daily human diet, including wheat, barley, and rye.
Gluten intake is associated with the development of celiac disease (CD) and related disorders such as diabetes mellitus
type I, depression, and schizophrenia. However, until now, there is no consent about the possible deleterious effects of
gluten intake because of often failing symptoms even in persons with proven CD. Asymptomatic CD (ACD) is present
in the majority of affected patients and is characterized by the absence of classical gluten-intolerance signs, such as
diarrhea, bloating, and abdominal pain. Nevertheless, these individuals very often develop diseases that can
be related with gluten intake. Gluten can be degraded into several morphine-like substances, named gluten exorphins.
These compounds have proven opioid effects and could mask the deleterious effects of gluten protein on
gastrointestinal lining and function. Here we describe a putative mechanism, explaining how gluten could “mask” its
own toxicity by exorphins that are produced through gluten protein digestion.
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Background
Gluten is the main structural protein complex of wheat
consisting of glutenins and gliadins. Glutenins are poly-
mers of individual proteins and are the fraction of wheat
proteins that are soluble in dilute acids. Prolamins are
the alcohol-soluble proteins of cereal grains that are
specifically named gliadins in wheat [1], which can be
further degraded to a collection of opioid-like polypep-
tides called exorphins in the gastrointestinal tract [2].
Gliadin epitopes from wheat gluten and related prola-
mins from other gluten-containing cereal grains, includ-
ing rye and barley, can trigger celiac disease (CD) in
genetically susceptible people [3], and accumulating data
provide evidence for the deleterious effects of gluten
intake on general human health. Nevertheless, until
now, there is no consent about the possible detrimental
health effects of gluten intake because of often failing
gastrointestinal symptoms even in individuals with
proven CD. By describing our “silent opioid hypothesis,”
we hope to shine light on this highly conflictive scientific
item. Our review process and literature search was based
on the use of the following key words: gluten, gliadin,
celiac disease, asymptomatic celiac disease, gluten and
transglutaminase, gluten and exorphins, gluten and in-
tolerance, gluten and DPP IV, gluten and substance P,
DPP IV, gluten and neoantigens, celiac disease and epi-
demiology, and gluten-free diet. Literature inclusion cri-
teria included in vitro, in vivo, and human trial studies;
indexed publications; full-text papers; and research
methodology. Papers were excluded when not indexed
and when methodology did not reach minimal criteria,
and papers older than 2005 were excluded when more
actual publications were available.
Asymptomatic celiac disease
CD normally presents itself with a number of typical
signs and symptoms of malabsorption: diarrhea, muscle
wasting, and weight loss. Other gastrointestinal (GI)
symptoms like abdominal pain, bloating, and flatulence
are also common. Curiously, a large group of patients
that have been diagnosed with CD through screening for
CD-specific antibodies and duodenal biopsy [3, 4] lack
these classical symptoms, a condition that is also re-
ferred to as “asymptomatic CD” (ACD). Many disorders
are present in patients with ACD, including diabetes
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mellitus type I [5, 6], severe hypoglycemia in diabetes
mellitus type I [7], psoriasis [8], sleep apnea in children
[9], neoplasia [10], atopic dermatitis [11], depression [8],
subclinical synovitis in children [12], autism [13],
schizophrenia [14], and irritable bowel syndrome (IBS)
[8], suggesting that gluten intake is related to the devel-
opment of these conditions.
ACD is present in a large group of diagnosed celiac
patients [15, 16]. A study based on the data of the
National Health and Nutrition Examination Survey
showed that only 17 % of patients with serologically
diagnosed CD suffer from the classical celiac symptoms
[17]. A human study in 2089 elderly individuals looking
for possible persistence of anti-gliadin antibody (AGA)
positivity showed that 54 % of the AGA-positive patients
suffered from intestinal inflammation, but only a small
number of them complained about gastrointestinal
symptoms [18]. The rate of elderly people suffering from
mild inflammation in the gut mucosa and being AGA-
negative is, according to a recent Swedish-population-
based study, only 3.8 % [19], again showing that gluten
can cause inflammatory injury in the gut, without suffer-
ing any gastrointestinal symptoms. The presence of pos-
sible ACD is further recognized by the National Institute
for Health and Care Excellence (UK) [20]. According to the
guidance for CD screening issued in 2009, it is recom-
mended to screen for CD when patients suffer from
diabetes mellitus type I, IBS, thyroid hormone distur-
bances, Addison’s disease, epilepsy, lymphoma, rick-
ets, repetitive miscarriage, Sjögren’s disease, and
Turner disease. The following question arises: why
do patients with ACD, with proven inflammatory
signs, not suffer from pain, bloating, and other typ-
ical symptoms? Could it be that substances present
in gluten with opioid effects mask the deleterious ef-
fects, functioning as masking compounds of gastro-
intestinal symptoms, converting the causal factor of
CD, gluten, into a silent killer?
CD is characterized by the presence of serum
antibodies against tissue transglutaminase
The most reliable way to diagnose CD is through small
intestinal biopsy and measurement of the presence of
serum antibodies against tissue transglutaminase (tTG),
the main endomysial auto-antigen in CD [21–23]. Tissue
TG deamidates glutamine residues from the gliadin pep-
tide into glutamic acid, leading to enhanced immuno-
genicity of the resulting modified peptides. In addition,
tTG can, in the absence of any other protein substrate,
crosslink with gliadin, producing a tTG-gliadin complex,
which can be considered a neo-antigen with possible
immune toxicity [24, 25]. Both symptomatic and asymp-
tomatic CD are associated with certain immune system-
related genetic polymorphisms, of which the HLA-DQ2
and HLA-DQ8 polymorphisms are expressed in the ma-
jority of CD patients [3]. However, many more genes, all
related to a more pro-inflammatory activity of the
immune system, are also linked with increased CD
susceptibility [26]. A recent study by Sironi et al. [27]
showed that several interleukin/interleukin receptor
genes, involved in the pathogenesis of CD, have been
subjected to pathogen-driven selective pressure. Particu-
larly, CD alleles of IL18-RAP, IL18R1, IL23, IL18R1, and
the intergenic region between IL2 and IL21 display
higher frequencies in populations exposed to high
microbial/viral loads, suggesting that these variants
protected humans against pathogens. Since CD occurred
after the increase of hygiene management and the
incorporation of cereals into the human diet, it can be
assumed that individuals bearing these genotypes are
better protected against pathogens but at the same time
are more susceptible for autoimmune diseases in general
and CD specifically [28]. Although the above-described
events explain the development of the typical inflamma-
tory symptoms of CD and even the flattening of the gut
lining through this immune response, they do not
explain the phenomenon that many patients suffer from
ACD at the level of the intestine and often, in parallel,
suffer from extra-gastrointestinal disorders [8].
Gliadin is degraded to a collection of
polypeptides called exorphins in the
gastrointestinal tract
Breakdown of gliadin from wheat is achieved through
hydrolysation by intestinal pepsin, leucine aminopeptidase,
and elastase, resulting in the release of immune-reactive
and opioid-like peptides, including gliadinomorphin-7
(Tyr-Pro-Gln-Pro-Gln-Pro-Phe) from α-gliadin [2]. Further
breakdown of these peptides, which are rich in proline,
depends on the enzyme dipeptidyl peptidase IV (DPP IV),
capable of cleaving N-terminal dipeptides with proline at
the second (penultimate) position [29–31]. The remaining
tripeptide (in the case of gliadinomorphin-7) with proline
in the center is slowly hydrolyzed and acts as a selective
competitive inhibitor for DPP IV [32–34].
Whereas total breakdown of gliadin into isolated
amino acids prevents the presence of the gluten epitopes
which are known to provoke a pro-inflammatory re-
sponse of the immune system in genetically susceptible
people [35, 36], a possible DPP IV deficiency/inactivity
could result in the incomplete breakdown of gluten, and
thereby increase the presence of immune-reactive and
opioid-like peptides, also known as gluten exorphins
[36–39]. Gluten is not the only source of exorphins.
Dairy products and certain vegetables such as soy and
spinach also contain proteins, which can be converted in
bioactive exorphins [40].
Pruimboom and de Punder Journal of Health, Population and Nutrition  (2015) 33:24 Page 2 of 8
Gliadin from gluten and casein from dairy products
show surprisingly high substrate specificity for DPP IV
when compared with other endogenous DPP IV sub-
strates. For example, DPP IV shows higher affinity for
gliadin and casein than for substance P (SP) [41] and
glucagon-like peptide (GLP) [42]. Gliadin is highly
specific for DPP IV [36], which is further evidenced by
its binding affinity with human DPP IV. By using an en-
zyme-linked immunosorbent assay, it was shown that
binding of gliadin and casein to DPP IV inhibited
DPP IV binding to anti-DPP IV by 52 and 44 %, re-
spectively [43]. The fact that gliadin has a high
affinity for DPP IV might explain why so many pa-
tients with proven CD are asymptomatic. Inhibition
of DPP IV by gliadin can result in increased levels of
non-metabolized gliadin molecules with opioid activity
that can inhibit the typical abdominal pain associated
with classical CD (Fig. 1).
Opioid pathways could be responsible for the
development of ACD
It is surprising that a large group of patients, positive for
the presence of CD antibodies and with proven histo-
logical CD, do not suffer from any gastrointestinal symp-
toms. If it is the opioid effects of gluten itself masking
the classical symptoms of CD, then symptoms should be
provoked when patients are given naloxone, a natural
antagonist of morphine.
Opioid effects on intestinal transit time
Gastric emptying and intestinal transit are influenced by
endogenous and exogenous opioid substances. It is
known for long that morphine increases gastrointestinal
transit time in humans and that this can be reversed by
naloxone [44]. Early research showed that gluten exor-
phins induced a significant increase in transit time, and
this effect was abolished when naloxone was adminis-
tered [45]. A more recent study supports these early
findings. In a single-center study, Urgesi et al. [46]
observed that patients suffering from CD show a sig-
nificantly longer small bowel transit time. In the
discussion, the authors mention different pathways
explaining their findings but do not mention the
possible effect of opioids on intestinal transit time.
Gluten-derived exorphins mimic endogenous opioid
activity
Stimulation of insulin production after meal intake is
considered an endogenous opioid activity. Early research
in rodents showed that oral administration of gluten
exorphin A5 stimulated insulin production after food
intake. The postprandial increase of insulin release by
gluten exorphin was completely abolished by the opioid
antagonist naloxone, implying that gluten exorphins
maintain bioavailability for the peripheral nervous
system within the gastrointestinal tract and pancreatic
tissues [47]. Elevated circulating prolactin levels were
Fig. 1 The development of symptomatic and asymptomatic CD and NCGS. Incomplete gluten breakdown results in inhibition of DPP IV and the
possible increase of SP, leading to intestinal and extra-intestinal gluten-induced disorders. Gluten-derived DPP IV inhibition also increases the
presence of GIP and GLP in the gut, leading to improved glucose homeostasis
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observed in individuals diagnosed with CD [48]. A
short gluten-free diet period lowered prolactin levels
in these patients, suggesting that gluten (or gluten-
derived substances), similar to endogenous opioids,
directly affects prolactin secretion. This was further
evidenced by Fanciulli et al. [49]. In rats, by using an
opioid antagonist unable to cross the blood-brain bar-
rier (naloxone methobromide), intracerebroventricular
(ICV)-injected gluten exorphins stimulated prolactin
release through activation of opioid receptors prob-
ably also outside the brain.
Gluten exorphins influence behavior and pain perception
A recent review of the literature concluded that food-
derived exorphins are bioactive and affect behavioral
traits such as spontaneous behavior, memory, and pain
perception in rodents. The highest behavioral influence
was measured for casein and spinach-derived exorphins
(respectively, B-casomorphin and rubiscolin) [50]. Only
one of the reviewed studies described the effects of glia-
din exorphins in this context. Takahashi et al. [51]
showed that ICV-administered gliadin exorphin A5 in-
duced antinociceptive effects and orally delivered gliadin
exorphin A5 modified learning and anxiety behavior
during several laboratory stressors in mice, thus indicat-
ing that orally delivered exorphins can influence both
the peripheral and central nervous system and
suggesting that gluten exorphins possess opioid activity
that could potentially mask symptoms in ACD patients.
Besides explaining the lack of intestinal symptoms
through gluten exorphin opioid activity in individuals
suffering from ACD, DPP IV inhibition by gluten intake
can have many other consequences on human health.
DPP IV inhibition is known to have anti-diabetic effects
but at the same time could be responsible for the pres-
ence of extra-intestinal symptoms and disorders in ACD
and the occurrence of intestinal and extra-intestinal
symptoms and disorders in CD and non-celiac gluten
sensitivity (NCGS) patients (described below).
DPP IV inhibition by gluten intake
DPP IV blockage by gliadin peptides improves glucose
homeostasis
Casein is not the only protein competing with gluten as
a substrate for DPP IV (a nice overview of natural DPP
IV substrates is provided by Gorrel et al. [52]). Other
N-terminal dipeptides with proline at the second
position, like the incretins, GLP and glucose-dependent
insulinotropic polypeptide (GIP), both important regula-
tors of glucose metabolism and essential to gut function,
compete with gluten as substrates for DPP IV [52–57].
Carbohydrate intake increases the secretion of both incre-
tins, which are normally rapidly broken down by DPP IV
[58]. In a recent review [58], it is described how the
inhibiting effect of gliadin on DPP IV increases the pres-
ence of GLP and GIP, by using whole wheat as a natural
DPP IV inhibitor. DPP IV inhibition by gliadin could ex-
plain the “health promoting” effects of whole wheat intake,
as the suppression of GLP and GIP breakdown has
anti-diabetic effects [58] (Fig. 1). Contrasting data
were found in a randomized, controlled, and open-
labeled study [59]. Two days of DPP IV inhibition in-
creased GLP and GIP levels but did not affect glu-
cose values, transit time, or gastric emptying in
healthy subjects, suggesting that short exposure to
DPP IV inhibition does not affect any function re-
lated with DPP IV. The latter makes sense when ob-
serving the toxic effects of gluten as a natural DPP
IV inhibitor. When patients suffering from NCGS
followed a gluten-free diet and were re-challenged
with gluten intake, it took approximately 7 days be-
fore new symptoms were provoked [60]. Longer use
of gluten and synthetic DPP IV inhibitors have been
shown to influence gastric emptying and transit time
significantly. It is even so that deceleration and
slowing of transit time are considered the most im-
portant mechanisms by which DPP IV inhibitors in-
fluence glucose homeostasis [56, 61, 62].
DPP IV blockage by gliadin peptides induces intestinal
and extra-intestinal disorders
Breakdown of SP is also dependent on DPP IV activity.
SP has neurological, immunological, and endocrino-
logical functions and influences pain sensitivity, gut
peristaltic, inflammation, and social interaction [63]. In-
creased concentrations of SP in the gut can produce ab-
dominal pain with diarrhea [64] and angioedema with
swelling and abdominal pain [65]. High SP levels in the
gut can even produce pancreatitis together with abdom-
inal pain, diarrhea, and vomiting [66]. A recent double-
blind placebo-controlled human trial showed that the in-
take of a small amount of gluten (4.375 g/day for 1 week)
significantly increased intestinal and extra-intestinal
symptoms in individuals with self-reported gluten sen-
sitivity [67]. Typical intestinal symptoms such as
bloating and abdominal pain were increased after
1 week of gluten intake, as were extra-intestinal symp-
toms, such as depression and apthous stomatitis. Be-
cause in patients suffering from NCGS no known
intestinal lesions or other biomarkers such as anti-
bodies against gluten/gliadin/self-antigens seem to be
present [68], their symptoms have to be explained by
different pathways. NCGS presents itself with intes-
tinal symptoms like diarrhea, abdominal discomfort,
and flatulence, while headache, lethargy, attention-
deficit/hyperactivity disorder, ataxia, or oral ulceration
appears as an extra-intestinal symptom [3, 67]. Most,
if not all, of these symptoms can be explained by
Pruimboom and de Punder Journal of Health, Population and Nutrition  (2015) 33:24 Page 4 of 8
increased levels of SP [64, 69, 70], suggesting that, in
NCGS patients, gliadin blocks DPP IV activity and
thereby inhibits SP breakdown. Thus, interventions
targeting SP release in this group of patients could be
a possible strategy to alleviate their intestinal and
extra-intestinal symptoms [67] (Fig. 1).
DPP IV inhibition increases the development of
angioedema
DPP IV inhibition by synthetic inhibitors, such as
sitagliptin, is known to increase the possibility of
developing angioedema [71]. CD produces the same
symptoms as angioedema, and both disorders are so
similar that, in general, it is advised to screen people
with hereditary angioedema for CD [72]. Skin disor-
ders, CD, and angioedema seem to be associated as
seen in patients suffering from gluten-induced chronic
urticaria [73] of which approximately 40 % also
experience angioedema [74]. Even guidelines for the
management of urticaria are similar as for angioedema
[74, 75], suggesting that both disorders have the same
etiology, which could be CD and/or increased levels of
SP through DPP IV inhibition. A study by Ramsay
et al. [76] indicated that patients with gastrointestinal
disorders (CD, morbus Crohn, colitis) suffer from
mast-cell-induced inflammation. Interestingly enough,
mast-cell inflammation can be induced by SP [77].
DPP IV inhibition by gluten would also explain the re-
lationship between gluten intake and skin disorders
[78, 79]. Many skin diseases, including acne vulgaris,
are associated with higher serum levels of SP [69],
which can be induced by blockage of DPP IV [65]. An-
other gluten intake-related disorder, major depression,
is also related with DPP IV inhibition; low serum DPP
IV is an important marker for depression [80], and
gluten could function as an inhibitor of DPP IV.
Gliadin peptides can cause anatomical changes at the
level of the brain
Recent research in humans has shown that gluten intake
can even cause anatomical changes at brain level,
although neurological symptoms are absent. Anatomical
MRI shows silent neurological changes, including bilat-
eral decrease in cortical gray matter and caudate nuclei
volumes in celiac patients compared to controls [81].
Negative correlations were found between the duration
of the disease and the volumes of the affected regions.
Similar neurological changes were observed in a retro-
spective examination of the brain by MRI of patients
suffering from biopsy-proven CD who were referred for
a neurological opinion by their gastroenterologist [82].
Patients were divided into subgroups based on their
primary neurological complaint (balance disturbance,
headache, and sensory loss). The outcome was that CD
patients suffer from a significant loss of cerebellar vol-
ume compared with healthy controls. Affected area were
brain regions below and above the tentorium cerebelli.
These changes were the highest in the headache sub-
group and unexpected for the patient’s age. The head-
ache group had an average loss of white matter in these
regions two times more than the subgroup with balance
disturbance and six times more than the subgroup suf-
fering from sensory loss. One possible explanation for
the loss of white matter in people suffering from CD is
the presence of gluten-induced autoimmune vasculitis
[83]. Another more recent hypothesis explaining the loss
of white matter caused by reactions against gluten is re-
lated with the complementary immune system. The
complement protein C1Q is known to bind and help
eliminate complexes of immune globulins bound to anti-
gens [84]. C1Q further is considered a “punishment fac-
tor” of the central neurological system, produced by
strong synapsis and marking weak synapsis for possible
phagocytosis by neighboring glia cells [85]. The process
of synapsis breakdown should be considered normal in
early life with the purpose of remodeling the central ner-
vous system during neurological development [86]. In-
creased expression of C1Q has been observed in
patients suffering from Alzheimer [87], autism [88], and
schizophrenia [89]. Severance et al. [84] showed that
C1Q binds preferentially to immune globulins coupled
with casein and gluten antigens. Their results suggest
that the increased expression of C1Q increased synaptic
breakdown and could be responsible for schizophrenia
onset. We speculate that the increased presence of
gliadin peptides, induced by DPP IV inhibition, could be
responsible for stimulating C1Q expression and, thereby
increases disease susceptibility for these neurodevelop-
mental and neurodegenerative disorders.
Conclusions
The precise pathway leading to the development of
ACD still needs to be discovered. However, the puta-
tive mechanism presented in this review could explain
this intruding phenomenon. The incomplete break-
down of the gluten protein, resulting in the presence
of gliadin peptides with opioid effects, makes it plaus-
ible to suggest that the opioid effects of gluten exor-
phins could be responsible for the absence of classical
gastrointestinal symptoms of individuals suffering from
gluten-intake-associated diseases. Moreover, the partial
digestion of gluten, leading to DPP IV inhibition,
could also account for the presence of extra-
intestinal symptoms and disorders in ACD and the
occurrence of intestinal and extra-intestinal symp-
toms and disorders in CD and NCGS patients. If so,
then individuals suffering from any of these condi-
tions should be recognized in time and engage in a
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gluten-free lifestyle to prevent gluten-induced symp-
toms and disorders.
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